Application of chebulagic acid in preparation of medicament for treating diseases resulted from human enterovirus type 71 infection

A technology of human enterovirus and salicylic acid, applied in the field of medicine, can solve the problem that EV71 infection has no recognized effective drugs or vaccines.

Active Publication Date: 2013-05-22
INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Currently, there is no recognized s

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chebulagic acid in preparation of medicament for treating diseases resulted from human enterovirus type 71 infection
  • Application of chebulagic acid in preparation of medicament for treating diseases resulted from human enterovirus type 71 infection
  • Application of chebulagic acid in preparation of medicament for treating diseases resulted from human enterovirus type 71 infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1 challex acid inhibits the replication of EV71 virus in cells

[0021] In the EV71-infected human rhabdomyoma cell model, the newly cultured human rhabdomyoma cells were seeded into 96-well plates, and the number of cells per well was 2×10 4 indivual. After culturing in a 37°C incubator for 24 hours, the virus was inoculated.

[0022] The EV71 used is a popular strain in mainland China, the strain name is FY0805, isolated from Fuyang, Anhui, and the gene sequence is stored in NCBI as HQ882182. The dose of virus inoculated cells was 100TCID 50 , with a volume of 98 μl, and continue to culture in a 37°C incubator.

[0023] Challic acid was dissolved with normal saline, and administered 2 hours after the virus infected the cells, the drug volume was 2 microliters, and the untreated cells were given 2 microliters of normal saline. The cytopathic changes were observed within 72 hours, and the half effective inhibitory concentration of the drug was calculated ...

Embodiment 2

[0025] Therapeutic effect of embodiment 2 challex to EV71 virus infection mice

[0026] The purpose of this experiment is to verify the therapeutic effect of challex acid on EV71 virus infection in mice. The model used is a model of 10-day-old ICR mice infected with EV71 strain in mainland China. The strain is an adapted strain of the clinical isolate FY0805 in mice, the strain name is MP10, and the storage number of the gene sequence in NCBI is HQ712020. Take 1×10 7 TCID 50 After a dose of MP10 virus was injected intraperitoneally to infect 10-day-old ICR mice, the mice showed symptoms of hindlimb paralysis and weight loss within 4 days, and all died within 10 days after infection.

[0027] Using the above-mentioned model, the therapeutic effect of challeric acid was evaluated in vivo. The mice used were SPF grade ICR mice, 10 days old, half male and half male. First, intraperitoneal injection of MP10 virus for virus infection in mice, intraperitoneal injection of 2 hours...

Embodiment 3

[0029] Example 3 The effect of challelac on the viral load in EV71 virus infected mouse tissue

[0030] The viral load refers to the amount of virus per unit weight of the tissue, which is used to reflect the virus replication in the tissue.

[0031] The purpose of this experiment is to detect the effect of challeglic acid on the viral load in different tissues of EV71 virus-infected mice, so as to verify the inhibitory effect of challeglic acid on the replication of EV71 virus in vivo.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of chebulagic acid in the preparation of a medicament for treating diseases resulted from a human enterovirus type 71 infection. Preferably, the diseases resulted from the human enterovirus type 71 infection comprise foot and mouth disease, herpangina, viral meningitis, viral encephalitis, flaccid paralysis, pulmonary edema or viral myocarditis. In-vivo and in-vitro experiments show that chebulagic acid can inhibit replication and lesions of the human enterovirus type 71 in cells, has a good therapeutic effect for the diseases resulted from the human enterovirus type 71 infection, and has a clinical application prospect.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of challex acid in the preparation of medicines for treating diseases caused by human enterovirus 71 infection. Background technique [0002] Chebulagic acid, mainly found in the fruit of the C. chinensis plant, is structurally a hydrolyzed tannin, and its molecular formula is C 41 h 30 o 27 , its structural formula is as shown in formula I: [0003] [0004] Formula I [0005] Challelac has a variety of biological activities, including anti-inflammatory, anti-oxidant, antibacterial and anti-tumor. In addition, challex also inhibits the replication of a small number of viruses, such as herpes simplex virus (HSV), human hepatitis C virus (HCV) and human immunodeficiency virus (HIV). [0006] Human enterovirus 71 is a member of the genus Enterovirus of the Picornaviridae family, and belongs to human enterovirus A, referred to as EV71, which often causes hand, foot an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P31/14
Inventor 张连峰杨亚军刘江宁修晶辉
Owner INST OF LAB ANIMAL SCI CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap